Cardiovascular Disease Doctors in Palos Heights, IL Accepting Medicare

7 Cardiovascular Disease doctors found. Showing 1 - 7

Dr. Maitrayee Sundaresan Vadali, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12251 S 80th Ave Ste 1520, Palos Heights, IL 60463 Phone: 708-923-4200    Fax: 708-923-4201

Kristina Quinn Degesys, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12255 S 80th Ave Ste 205, Palos Heights, IL 60463 Phone: 708-923-4200    Fax: 708-923-4201

Dr. Tarek Mohamad Ahdab, MD, FACC Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12400 S Harlem Ave Ste 112, Palos Heights, IL 60463 Phone: 708-923-7650    Fax: 708-923-7655

Lisa Pudusseri, DO Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12255 S 80th Ave Ste 205, Palos Heights, IL 60463 Phone: 708-923-4200    Fax: 708-923-4201

Dr. Roland Whaley Winterfield Jr., M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12400 S Harlem Ave Ste 112, Palos Heights, IL 60463 Phone: 708-923-7650    Fax: 708-923-7655

Dr. Thomas J Quinn, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12251 S 80th Ave Ste 205, Palos Heights, IL 60463 Phone: 708-923-4200    Fax: 708-923-4201

Dr. Eric Teplitz, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12255 S 80th Ave, Palos Heights, IL 60463 Phone: 708-923-7650    Fax: 708-923-7655

News Archive

Sinovac Dalian JV to research, develop, produce and commercialize human-use vaccines

Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The JV will research, develop, produce and commercialize human-use vaccines. Sinovac will contribute its expertise and experience in developing and commercializing world-class vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.

Researchers identify genetic variant linked with the risk of prostate cancer

Researchers at Wake Forest University Baptist Medical Center and colleagues have identified the first genetic variant associated with aggressive prostate cancer, proving the concept that genetic information may one day be used in combination with other factors to guide treatment decisions.

White House: As deadline approaches, Obamacare sign ups top 6 million

Many questions remain about what this number means, though, including how many of those enrolling in new coverage had been uninsured before signing up and whether young and healthy people will be adequately represented.

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

New technique for tumor therapy under study

In the scientific journal PLoS ONE, Sara Bartels and Siegfried Weiss of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany now show how the bacteria migrate into tumours. A messenger substance from the immune system is the door opener: It makes blood vessels in the cancerous tissue permeable; enabling the bacteria to conquer and destroy the tumour.

Read more Medical News

› Verified 3 days ago